Evofem Biosciences (NASDAQ:EVFM) Shares Down 7.9%


Share on StockTwits

Evofem Biosciences, Inc. (NASDAQ:EVFM) shares were down 7.9% during trading on Tuesday . The stock traded as low as $3.71 and last traded at $4.09. Approximately 4,422,601 shares traded hands during trading, an increase of 0% from the average daily volume of 4,401,060 shares. The stock had previously closed at $4.44.

The firm has a 50 day simple moving average of $3.18 and a 200 day simple moving average of $2.72. The firm has a market capitalization of $332.44 million, a PE ratio of -2.02 and a beta of 0.07.

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE lifted its holdings in shares of Evofem Biosciences by 48.6% during the 2nd quarter. Bank of America Corp DE now owns 12,065 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 3,948 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Evofem Biosciences by 3.0% during the 4th quarter. Bank of New York Mellon Corp now owns 211,305 shares of the biotechnology company’s stock valued at $509,000 after buying an additional 6,120 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Evofem Biosciences by 15.9% during the 4th quarter. The Manufacturers Life Insurance Company now owns 51,158 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 7,030 shares during the period. Rhumbline Advisers lifted its holdings in shares of Evofem Biosciences by 11.8% during the 4th quarter. Rhumbline Advisers now owns 76,078 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 8,014 shares during the period. Finally, Citigroup Inc. lifted its holdings in shares of Evofem Biosciences by 218.8% during the 4th quarter. Citigroup Inc. now owns 14,609 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 10,026 shares during the period. Institutional investors and hedge funds own 44.84% of the company’s stock.

About Evofem Biosciences (NASDAQ:EVFM)

Evofem Biosciences, Inc, a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, a vaginal pH regulator for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women.

Featured Story: Initial Coin Offerings entail a high degree of risk

Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.